Edgar Filing: SIRONA DENTAL SYSTEMS, INC.

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

For the quarterly period ended March 31, 2011

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

þ	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2011

¨	Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission file number 000-22673

Sirona Dental Systems, Inc.

(Exact name of registrant as specified in charter)


Delaware		11-3374812
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

30-30 47^th Avenue, Suite 500, Long Island City, New York		11101
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code:

(718) 482-2011

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes ¨ No þ

As of May 4, 2011, the number of shares outstanding of the Registrant’s Common Stock, par value $.01 per share, was 55,761,081.

SIRONA DENTAL SYSTEMS, INC.

FORM 10-Q

FOR THE THREE MONTHS ENDED MARCH 31, 2011

Index


		Page
Part I.	Financial Information (Unaudited)		3

Item 1.	Financial Statements		3

	Condensed Consolidated Balance Sheets as of March 31, 2011 and September 30, 2010		3

	Condensed Consolidated Income Statements for the three and six months ended March 31, 2011 and 2010		5

	Condensed Consolidated Statements of Cash Flows for the six months ended March 31, 2011 and 2010		6

	Notes to the Condensed Consolidated Financial Statements		8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		23

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		34

Item 4.	Controls and Procedures		34

Part II.	Other Information		35

Item 1.	Legal Proceedings		35

Item 1A.	Risk Factors		35

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		35

Item 3.	Defaults upon Senior Securities		35

Item 4.	(Removed and Reserved)		35

Item 5.	Other Information		35

Item 6.	Exhibits		35

Signatures			37

Certifications

PART I

FINANCIAL INFORMATION (UNAUDITED)

ITEM 1.

FINANCIAL STATEMENTS

SIRONA DENTAL SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)


	Financial Statement Notes		March 31, 2011		September 30, 2010
			(unaudited)
			$’000s (except per share amounts)
ASSETS
Current assets
Cash and cash equivalents			$	300,136	$	251,767
Restricted cash				710		703
Accounts receivable, net of allowance for doubtful accounts of $1,639 and $1,681, respectively				113,245		82,952
Inventories, net		5		90,489		74,027
Deferred tax assets		9		24,005		20,570
Prepaid expenses and other current assets				15,097		24,139
Income tax receivable		9		4,948		3,533

Total current assets				548,630		457,691
Property, plant and equipment, net of accumulated depreciation and amortization of $105,443 and $90,713, respectively				118,225		102,686
Goodwill		6		677,610		656,465
Investments				2,364		2,317
Intangible assets, net of accumulated amortization of $401,167 and $371,303, respectively		6		346,495		362,722
Other non-current assets				2,773		2,229
Deferred tax assets		9		4,077		8,827

Total assets			$	1,700,174	$	1,592,937

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Trade accounts payable			$	48,167	$	42,737
Short-term debt and current portion of long-term debt		7		382,223		2,935
Income taxes payable		9		7,955		7,748
Deferred tax liabilities		9		1,211		1,456
Accrued liabilities and deferred income				89,201		105,209

Total current liabilities				528,757		160,085
Long-term debt		8		—		367,801
Deferred tax liabilities		9		134,014		138,190
Other non-current liabilities				6,453		6,556
Pension related provisions		12		55,418		52,672
Deferred income				55,000		60,000

Total liabilities				779,642		785,304

The accompanying notes are an integral part of these financial statements.


Shareholders’ equity
Preferred stock ($0.01 par value; 5,000,000 shares authorized; none issued and outstanding)			—			—
Common stock ($0.01 par value; 95,000,000 shares authorized;
55,768,804 shares issued and 55,741,081 shares outstanding at Mar. 31, 2011, and 55,333,304 shares issued and 55,305,581 shares outstanding at Sept. 30, 2010)			558			553
Additional paid-in capital			665,305			652,698
Treasury stock (27,723 shares at cost)			(284	)		(284	)
Excess of purchase price over predecessor basis			(49,103	)		(49,103	)
Retained earnings			253,550			181,846
Accumulated other comprehensive income	4		47,650			19,701

Total Sirona Dental Systems, Inc. shareholders’ equity			917,676			805,411

Noncontrolling interests			2,856			2,222

Total shareholders’ equity			920,532			807,633

Total liabilities and shareholders’ equity		$	1,700,174		$	1,592,937

The accompanying notes are an integral part of these financial statements.

SIRONA DENTAL SYSTEMS, INC.

AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)


	Financial Statement	Three months ended March 31,						Six months ended March 31,
	Notes	2011			2010			2011			2010
		$’000s (except per share amounts)						$’000s (except per share amounts)
Revenue		$	214,737		$	190,136		$	450,383		$	404,959
Cost of sales			99,048			90,803			204,280			193,256

Gross profit			115,689			99,333			246,103			211,703
Selling, general and administrative expense			70,581			60,354			133,904			120,206
Research and development			14,145			11,690			27,655			23,155
Provision for doubtful accounts and notes receivable			(47	)		72			21			136
Net other operating income	13		(2,500	)		(3,408	)		(5,000	)		(5,908	)

Operating income			33,510			30,625			89,523			74,114
(Gain)/Loss on foreign currency transactions, net			(4,336	)		5,049			(5,097	)		4,416
(Gain)/Loss on derivative instruments	14		(1,554	)		(1,712	)		81			(2,735	)
Interest expense, net			929			4,141			1,879			9,343
Other expense/(income)			343			404			(523	)		784

Income before taxes			38,128			22,743			93,183			62,306
Income tax provision	9		8,388			4,548			20,500			12,461

Net income			29,740			18,195			72,683			49,845
Less: Net income attributable to noncontrolling interests			428			656			979			1,131

Net income attributable to Sirona Dental Systems, Inc.		$	29,312		$	17,539		$	71,704		$	48,714

Income per share (attributable to Sirona Dental Systems, Inc. common shareholders):	10
- Basic		$	0.53		$	0.32		$	1.29		$	0.88
- Diluted		$	0.51		$	0.31		$	1.26		$	0.86
Weighted average shares - basic			55,529,619			55,122,944			55,432,272			55,044,832
Weighted average shares - diluted			57,221,163			56,610,111			57,056,605			56,490,563

The accompanying notes are an integral part of these financial statements.

SIRONA DENTAL SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Six months ended March 31,
	2011			2010
	$’000s
Cash flows from operating activities
Net income	$	72,683		$	49,845
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization		38,957			42,589
Loss on disposal of property, plant and equipment		—			15
Loss/(gain) on derivative instruments		81			(2,735	)
(Gain)/loss on foreign currency transactions		(5,097	)		4,416
Deferred income taxes		(7,250	)		(9,491	)
Amortization of debt issuance cost		597			586
Share-based compensation expense		4,479			8,048
Changes in assets and liabilities
Accounts receivable		(27,467	)		(7,288	)
Inventories		(13,280	)		(3,601	)
Prepaid expenses and other current assets		9,803			6,701
Restricted cash		20			109
Other non-current assets		(735	)		26
Trade accounts payable		3,957			3,353
Accrued interest on long-term debt		—			(1,412	)
Accrued liabilities and deferred income		(20,663	)		(25,309	)
Other non-current liabilities		234			4,037
Income taxes receivable		(1,410	)		1,506
Income taxes payable		(292	)		3,415

Net cash provided by operating activities		54,617			74,810
Cash flows from investing activities
Investment in property, plant and equipment		(23,618	)		(9,566	)
Proceeds from sale of property, plant and equipment		1			150
Purchase of intangible assets		(163	)		—
Purchase of long-term investments		(44	)		(230	)
Sale of businesses, net of cash sold		—			1,928

Net cash used in investing activities		(23,824	)		(7,718	)

The accompanying notes are an integral part of these financial statements.

SIRONA DENTAL SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Six months ended March 31,
	2011			2010
	$’000s
Cash flows from financing activities
Repayments of short-term and long-term debt		—			(78,072	)
Dividend distributions to noncontrolling interest		(487	)		—
Common shares issued under share based compensation plans		4,709			2,973
Tax effect of common shares exercised under share based compensation plans		4,135			1,181

Net cash provided by/(used in) financing activities		8,357			(73,918	)
Change in cash and cash equivalents		39,150			(6,826	)
Effect of exchange rate change on cash and cash equivalents		9,219			(11,833	)
Cash and cash equivalents at beginning of period		251,767			181,098

Cash and cash equivalents at end of period	$	300,136		$	162,439

Supplemental information
Interest paid	$	2,050		$	10,381
Interest capitalized		277			242
Income taxes paid		24,798			18,478
Sale of businesses, net of cash sold
Current assets	$	—		$	2,406
Non-current assets		—			550
Current liabilities		—			(867	)
Non-current liabilities		—			(161	)

	$	—		$	1,928

The accompanying notes are an integral part of these financial statements.

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. General

The Company and its Operations

Sirona Dental Systems, Inc. (“Sirona,” the “Company,” “we,” “us,” and “our” refer to Sirona Dental Systems, Inc. and its consolidated subsidiaries and their predecessors) is the leading manufacturer of high-quality, technologically advanced dental equipment, and is focused on developing, manufacturing and marketing innovative systems and solutions for dentists around the world. We offer a broad range of products across all major segments of the dental technology market including CEREC and our other CAD/CAM systems, digital intra oral and 2D and 3D panoramic imaging systems, treatment centers and instruments. The Company acquired Schick Technologies, Inc. (“Schick”) in 2006, in a transaction accounted for as a reverse acquisition (the “Exchange”), further expanding our global presence and product offerings and strengthening our research and development capabilities. Sirona has served equipment dealers and dentists worldwide for more than 130 years. The Company’s headquarters are located in Long Island City, New York with its primary facility located in Bensheim, Germany, as well as other support, manufacturing, assembling, and sales and service facilities located around the globe.

Basis of Presentation

These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Preparation of the interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions related to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as at the reporting date and the reported amounts of revenues and expenses for the interim period. Actual results could differ from those estimates. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information not misleading. The year-end condensed consolidated balance sheet data was derived from the audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These consolidated financial statements should be read in conjunction with the Consolidated Financial Statements and the Notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2010.

In the opinion of management, all adjustments (consisting of those of a normal recurring nature) considered necessary to present fairly the Company’s financial position as of March 31, 2011, and the results of operations and cash flows for the six months ended March 31, 2011 and 2010, respectively, as applicable to interim periods have been made. The results of operations for the six months ended March 31, 2011 are not necessarily indicative of the operating results for the full fiscal year or future periods.

All amounts are reported in thousands of U.S. Dollars ($), except per share amounts or as otherwise disclosed.

Fiscal year

The Company’s fiscal year is October 1 to September 30.

Principles of consolidation

The consolidated financial statements include, after eliminating inter-company transactions and balances, the accounts of Sirona Dental Systems, Inc. and its subsidiaries. The Company applies the equity method of accounting for investments in associated companies over which the Company has significant influence but does not have effective control.

2. Recently Issued Accounting Pronouncements

Adopted

Revenue Recognition

In October 2009, the Financial Accounting Standards Board (“FASB”) issued new accounting guidance for multiple-deliverable revenue arrangements (ASU 2009-13, Multiple-Deliverable Revenue Arrangements - a consensus of the FASB Emerging Issues Task Force). This new guidance establishes a selling price hierarchy for determining the selling price of a deliverable, replaces the term “fair value” in the revenue allocation with “selling price” to clarify that the allocation of revenue is based on entity-specific assumptions rather than assumptions of a marketplace participant, replaces the “residual

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

method” of allocation with the “relative selling-price method”, and requires that arrangement consideration be allocated at the inception of the arrangement to all deliverables applying this method, including proportional allocation of any discounts to each deliverable.

In October 2009, the FASB also issued new accounting guidance for revenue arrangements that include both tangible products and software elements (ASU 2009-14, Certain Revenue Arrangements that Include Software Elements – a consensus of the FASB Emerging Issues Task Force). This new guidance removes from the scope of the software revenue recognition guidance in ASC 985-605, Software Revenue Recognition, those tangible products containing software components and non-software components that function together to deliver the tangible product’s essential functionality. In addition, this guidance requires that hardware components of a tangible product containing software components always be excluded from the software revenue recognition guidance as well as provides further guidance on determining which software, if any, relating to the tangible product also would be excluded from the scope of software revenue recognition guidance.

The Company adopted these standards at the beginning of its first quarter of fiscal year 2011 for applicable arrangements that were entered into or materially modified on or after October 1, 2010. Implementation of these standards did not have a material impact on the Company’s condensed consolidated financial statements in the period under report and is not expected to significantly affect the timing and pattern of revenue recognition in future periods.

The Company’s main revenue stream results from the delivery of dental equipment. The Company also enters into revenue arrangements that consist of multiple deliverables of its product and service offerings. Additionally, certain products, primarily in our CAD/CAM and Imaging segments, may contain embedded software that functions together with the product to deliver the product’s essential functionality.

Revenue, net of related discounts and allowances, is recognized when products or equipment have been shipped, when persuasive evidence of the arrangement exists, the price is fixed or determinable, collectability is reasonably assured, title and risk of loss has passed to customers based on the shipping terms, no significant obligations remain, and allowances for discounts, returns, and customer incentives can be reliably estimated. The Company offers discounts to its distributors if certain conditions are met. Discounts and allowances are primarily based on the volume of products purchased or targeted to be purchased by the individual customer or distributor. Discounts are deducted from revenue at the time of sale or when the discount is offered, whichever is later. The Company estimates volume discounts based on the individual customer’s historical and estimated future product purchases. Returns of products, excluding warranty related returns, are infrequent and insignificant. Amounts received from customers in advance of product shipment are classified as deferred income until the revenue can be recognized in accordance with the Company’s revenue recognition policy.

Services: Service revenue is generally recognized ratably over the contract term as the specified services are performed. Amounts received from customers in advance of rendering of services are classified as deferred income until the revenue can be recognized upon rendering of those services.

Extended Warranties: The Company offers its customers an option to purchase extended warranties on certain products. The Company recognizes revenue on these extended warranty contracts ratably over the life of the contract. The costs associated with these extended warranty contracts are recognized when incurred.

Multiple-Element Arrangements (“MEAs”): Arrangements with customers may include multiple deliverables, including any combination of equipment, services, and extended warranties. The deliverables included in the Company’s MEAs are separated into more than one unit of accounting when (i) the delivered equipment has value to the customer on a stand-alone basis, and (ii) delivery of the undelivered service element(s) is probable and substantially in the control of the Company. Based on the new accounting guidance adopted October 1, 2010, arrangement consideration is then allocated to each unit, delivered or undelivered, based on the relative selling price (“RSP”) of each unit of accounting based first on vendor-specific objective evidence (“VSOE”) if it exists and then based on estimated selling price (“ESP”).

VSOE – In most instances, products are sold separately in stand-alone arrangements. Services are also sold separately through renewals of contracts with varying periods. The Company determines VSOE based on its pricing and discounting practices for the specific product or service when sold separately, considering geographical, customer, and other economic or marketing variables, as well as renewal rates or stand-alone prices for the service element(s).

ESP – The estimated selling price represents the price at which the Company would sell a product or service if it were sold on a stand-alone basis. When VSOE does not exist for all elements, the Company determines ESP for the arrangement element based on sales, cost and margin analysis, as well as other inputs based on its pricing practices. Adjustments for other market and Company-specific factors are made as deemed necessary in determining ESP.

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

After separating the elements into their specific units of accounting, total arrangement consideration is allocated to each unit of accounting according to the nature of the revenue as described above and application of the RSP method. Total recognized revenue is limited to the amount not contingent upon future transactions.

3. Employee Share-Based Compensation

Stock compensation expense under the Company’s stock option plans amounted to $2,568 and $4,479 for the three and six months ended March 31, 2011, respectively, and $4,109 and $8,048 for the three and six months ended March 31, 2010, respectively. These expenses include the effect of previous stock options, restricted stock unit (“RSU”) grants, and performance-based stock unit (“PSU”) grants.

On November 22, 2010, the Company granted 232,700 RSU’s and 12,800 PSU’s under its 2006 Equity Incentive Plan (“2006 Plan)”. The RSU grants vest over a period of four years (one third each during fiscal years 2013, 2014 and 2015). The PSU’s were granted to three executive officers of the Company and vest three years from the date of grant provided the Company achieves earnings targets specified in the grant. The value of each RSU and PSU grant is determined by the closing price at the date of grant of $36.78.

On December 8, 2009, the Company granted 188,000 RSU’s under the 2006 Plan. The RSU grants vest over a period of four years (one third each at December 8, 2011, 2012 and 2013). The value of each RSU is determined by the closing price at the date of grant of $34.45.

The 2006 Plan provides for granting in total up to 4,550,000 stock options, incentive stock, and RSU’s to employees, directors, and consultants and received stockholder approval at the Company’s Annual Meeting of Stockholders held on February 27, 2007, and was amended on February 25, 2009. As of March 31, 2011, 1,393,934 shares were available for future grant under the 2006 Plan.

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

4. Comprehensive Income/(Loss) and Change in Equity


	Three months ended March 31,									Six months ended March 31,
	Changes in Equity attributable to									Changes in Equity attributable to
	Sirona Dental Systems, Inc.			Noncontrolling Interests			Total Change in Equity for the Period			Sirona Dental Systems, Inc.			Noncontrolling Interests			Total Change in Equity for the Period
	$’000s									$’000s
As of March 31, 2011
Comprehensive Income:
Net Income	$	29,312		$	428		$	29,740		$	71,704		$	979		$	72,683
Other Comprehensive Income
Cumulative translation adjustments		39,920			97			40,017			28,029			142			28,171
Unrecognized elements of pension cost, net of tax		(40	)		—			(40	)		(80	)		—			(80	)

Total Other Comprehensive Income		39,880			97			39,977			27,949			142			28,091

Total Comprehensive Income		69,192			525			69,717			99,653			1,121			100,774

Transactions with shareholders:
Stock-based compensation activities		8,599			—			8,599			12,612			—			12,612
Dividend distribution to noncontrolling interest		—			(487	)		(487	)		—			(487	)		(487	)

Total transactions with shareholders		8,599			(487	)		8,112			12,612			(487	)		12,125

Total Change in Equity for the period	$	77,791		$	38		$	77,829		$	112,265		$	634		$	112,899


	Three months ended March 31,									Six months ended March 31,
	Changes in Equity attributable to									Changes in Equity attributable to
	Sirona Dental Systems, Inc.			Noncontrolling Interests			Total Change in Equity for the Period			Sirona Dental Systems, Inc.			Noncontrolling Interests			Total Change in Equity for the Period
	$’000s									$’000s
As of March 31, 2010
Comprehensive Income/(Loss):
Net Income	$	17,539		$	656		$	18,195		$	48,714			1,131		$	49,845
Other Comprehensive Income/(Loss)
Cumulative translation adjustments		(38,668	)		(26	)		(38,694	)		(49,448	)		(18	)		(49,466	)
Unrecognized elements of pension cost, net of tax		(77	)		—			(77	)		(164	)		—			(164	)

Total Other Comprehensive Loss		(38,745	)		(26	)		(38,771	)		(49,612	)		(18	)		(49,630	)

Total Comprehensive Income/(Loss)		(21,206	)		630			(20,576	)		(898	)		1,113			215

Transactions with shareholders:
Stock-based compensation activities		3,573			—			3,573			9,364			—			9,364
Purchase of shares from noncontrolling interest		(818	)		(498	)		(1,316	)		(818	)		(498	)		(1,316	)

Total transactions with shareholders		2,755			(498	)		2,257			8,546			(498	)		8,048

Total Change in Equity for the period	$	(18,451	)	$	132		$	(18,319	)	$	7,648			615		$	8,263

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

5. Inventories, net


	March 31,			September 30,
	2011			2010
	$’000s
Finished goods	$	56,683		$	51,102
Work in progress		16,442			12,646
Raw materials		32,456			23,342

		105,581			87,090
Inventory reserve		(15,092	)		(13,063	)

	$	90,489		$	74,027

6. Intangible Assets and Goodwill


	Gross		Accumulated amortization		Net
	$’000s
As of March 31, 2011
Patents & Licenses	$	147,112	$	71,586	$	75,526
Trademarks		136,183		478		135,705
Technologies and dealer relationships		464,289		329,103		135,186
Prepayments for intangible assets		78		—		78

		747,662		401,167		346,495
Goodwill		677,610		—		677,610

Total intangible assets	$	1,425,272	$	401,167	$	1,024,105


	Gross		Accumulated amortization		Net
	$’000s
As of September 30, 2010
Patents & Licenses	$	150,706	$	71,965	$	78,741
Trademarks		131,908		428		131,480
Technologies and dealer relationships		451,333		298,910		152,423
Prepayments for intangible assets		78		—		78

		734,025		371,303		362,722
Goodwill		656,465		—		656,465

Total intangible assets	$	1,390,490	$	371,303	$	1,019,187

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The change in the value of goodwill and of intangible assets from September 30, 2010 to March 31, 2011 is mainly attributable to foreign currency fluctuations, with an increase of $21,871 in goodwill and $10,603 in intangible assets. Goodwill has been reduced by $706 as a result of tax benefits received subsequent to the Exchange for options that were vested and included in the determination of purchase price at the time of that acquisition.

7. Short-Term Debt and Current Portion of Long-Term Debt

The components of short-term debt are as follows:


	March 31, 2011		September 30, 2010
	$’000s
Senior Term Loans (Tranches A1/A2, variable rate repayable in November 2011)	$	378,408	$	—
Accrued interest on long-term debt		—		319
Other short-term debt		3,815		2,616

	$	382,223	$	2,935

8. Long-Term Debt

The components of long-term debt are as follows:


	March 31, 2011		September 30, 2010
	$’000s
Bank loans:
Senior term loan, Tranche A1, variable rate repayable in November 2011	$	—	$	105,063
Senior term loan, Tranche A2, variable rate repayable in November 2011		—		263,057

		—		368,120
Less current portion		—		319

	$	—	$	367,801

Senior Term Loans

On November 22, 2006, Sirona Dental Systems, Inc. entered into a Senior Facilities Agreement (the “Senior Facilities Agreement”) as original guarantor, with all significant subsidiaries of Sirona as original borrowers and original guarantors. Initial borrowings under the Senior Facilities Agreement plus excess cash were used to retire the outstanding borrowings under the Company’s previous credit facilities.

The Senior Facilities Agreement includes: (1) a term loan A1 in an aggregate principal amount of $150 million (the “tranche A1 term loan”) available to Schick Technologies, Inc., a New York company and wholly-owned subsidiary of Sirona (“Schick NY”), as borrower; (2) a term loan A2 in an aggregate principal amount of Euro 275 million (the “tranche A2 term loan”) available to Sirona’s subsidiary, Sirona Dental Services GmbH, as borrower; and (3) a $150 million revolving credit facility available to Sirona Dental Systems GmbH, Schick NY and Sirona Dental Services GmbH, as initial borrowers. The

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

revolving credit facility is available for borrowing in Euro, U.S. Dollars, Yen or any other freely available currency agreed to by the facility agent. The facilities are made available on an unsecured basis. Subject to certain limitations, each European guarantor guarantees the performance of each European borrower, except itself, and each U.S. guarantor guarantees the performance of each U.S. borrower, except itself. There are no cross-border guarantees since all guarantees are by entities that have the same functional currency as the currency in which the respective guaranteed borrowing is denominated.

Each of the senior term loans are to be repaid in three annual installments beginning on November 24, 2009 and ending on November 24, 2011. Of the amounts borrowed under the term loan facilities, 15% was due on November 24, 2009, 15% was due on November 24, 2010 and 70% is due on November 24, 2011. The senior debt repayment tranche originally scheduled for November 24, 2009 was prepaid on May 11, 2009 in the amount of $78.6 million, and the senior debt repayment tranche originally scheduled for November 24, 2010 was prepaid on March 31, 2010 in the amount of $78.1 million. At the Company’s current Debt Cover Ratio, the facilities bear interest of Euribor, for Euro-denominated loans, and Libor for the other loans, plus a margin of 45 basis points for both.

The Senior Facilities Agreement contains a margin ratchet. Pursuant to this provision, which applies from November 24, 2007 onwards, the applicable margin will vary between 90 basis points and 45 basis points per annum according to the Company’s leverage multiple (i.e. the ratio of consolidated total net debt to consolidated adjusted EBITDA as defined in the Senior Facilities Agreement). Interest rate swaps were established for 66.6% of the interest until March 2010. These swaps expired on March 31, 2010 and were not renewed. The interest rate swaps fixed the LIBOR or EURIBOR element of interest payable on 66.7% of the principal amount of the loans for defined twelve and thirteen month interest periods over the lifetime of the swaps, respectively. The defined interest rates fixed for each twelve or thirteen month interest period ranged from 3.50% to 5.24%. Settlement of the swaps was required on a quarterly basis.

The Senior Facilities Agreement contains restrictive covenants that limit Sirona’s ability to make loans, make investments (including in joint ventures), incur additional indebtedness, make acquisitions or pay dividends, subject to agreed-upon exceptions. The Company has agreed to certain financial debt covenants in relation to the financing. The covenants stipulate that the Company must maintain certain ratios in respect of interest payments and defined earnings measures. If the Company breaches any of the covenants, the loans will be become repayable on demand.

Debt issuance costs of $5.6 million were incurred in relation to the financing in November 2006 and were capitalized as deferred charges and are amortized using the effective interest method over the term of the loan.

9. Income Taxes

For the first six months of fiscal year 2011, an estimated effective tax rate of 22% has been applied, compared to an estimated effective tax rate of 20% for the first six months of fiscal year 2010 and an effective tax rate for fiscal year 2010 of 20.6%.

The Company’s effective tax rate may vary significantly from period to period, and can be influenced by many factors. These factors include, but are not limited to, changes in the mix of earnings in countries with differing statutory tax rates (including as a result of business acquisitions and dispositions), changes in the valuation of deferred tax assets and liabilities, the results of audits and examinations of previously filed tax returns, tax planning initiatives, tax characteristics of income, as well as the timing and deductibility of expenses for tax purposes. The Company’s effective tax rate differs from the United States federal statutory rate of 35% primarily as a result of lower effective tax rates on certain earnings outside of the United States. The distribution of lower-taxed foreign earnings to the U.S. would generally increase the Company’s effective tax rate.

With limited exception, the Company and its subsidiaries are no longer subject to U.S. federal, state and local or non-U.S. income tax examinations by taxing authorities for tax returns filed with respect to periods prior to fiscal year 2005.

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

10. Income per Share

The computation of basic and diluted income per share is as follows:


	Three months ended March 31,				Six months ended March 31,
	2011		2010		2011		2010
	$’000s (except for share amounts)				$’000s (except for share amounts)
Net income attributable to Sirona Dental Systems, Inc. common shareholders	$	29,312	$	17,539	$	71,704	$	48,714

Weighted average shares outstanding - basic		55,529,619		55,122,944		55,432,272		55,044,832
Dilutive effect of stock-based compensation		1,691,544		1,487,167		1,624,333		1,445,731

Weighted average shares outstanding - diluted		57,221,163		56,610,111		57,056,605		56,490,563

Net income per share
Basic	$	0.53	$	0.32	$	1.29	$	0.88

Diluted	$	0.51	$	0.31	$	1.26	$	0.86

Stock options to acquire 80,250 shares of Sirona’s common stock that were granted in connection with the Company’s stock option plans were not included in the computation of diluted earnings per share for the three months ended March 31, 2010 because the options’ underlying exercise prices were greater than the average market price of Sirona’s common stock for the period. There were no out of the money options for the three and six months ended March 31, 2011.

11. Product warranty

The following table provides the changes in the product warranty accrual for the three months ended March 31, 2011 and 2010:


	Three months ended March 31,						Six months ended March 31,
	2011			2010			2011			2010
	$’000s						$’000s
Balance at beginning of the period	$	8,458		$	12,083		$	8,972		$	11,506
Accruals for warranties issued during the period		4,928			4,828			9,032			11,549
Warranty settlements made during the period		(5,256	)		(4,570	)		(9,726	)		(10,512	)
Translation adjustment		424			(715	)		276			(917	)

Balance at end of the period	$	8,554		$	11,626		$	8,554		$	11,626

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

12. Pension Plans

Components of net periodic benefit costs are as follows:


	Three months ended March 31,						Six months ended March 31,
	2011			2010			2011			2010
	$’000s						$’000s
Service cost, net	$	65		$	65		$	129		$	135
Interest cost		608			635			1,213			1,312
Amortization of actuarial gains		(40	)		(112	)		(80	)		(233	)

Net periodic benefit cost	$	633		$	588		$	1,262		$	1,214

13. Net Other Operating Income

Net other operating income for the three and six months ended March 31, 2011 and 2010 was $5.0 million and $5.9 million, respectively. In both periods, net other operating income included $2.5 million (three months) and $5.0 million (six months) of income resulting from the amortization of the deferred income relating to the Patterson exclusivity payment. In the three and six months ended March 31, 2010, net other operating income included a gain from the sale of a subsidiary in Italy of $0.9 million.

14. Derivative Instruments and Hedging Strategies

Our operations are exposed to market risks from changes in foreign currency exchange rates and interest rates. In the normal course of business, these risks are managed through a variety of strategies, including the use of derivatives.

Interest Rate Risk

The Company is exposed to interest rate risk associated with fluctuations in the interest rates on its variable interest rate debt. In order to manage this risk, the Company entered into interest rate swap agreements that convert the debt’s variable interest rate to a fixed interest rate. While these swap agreements were considered to be economic hedges, they are not designated as hedging instruments under ASC 815.

Interest rate swaps were established for 66.6% of the interest until March 2010. These swaps expired on March 31, 2010 and were not renewed. The interest rate swaps fixed the LIBOR or EURIBOR element of interest payable on 66.7% of the principal amount of the loans for defined twelve and thirteen month interest periods over the lifetime of the swaps, respectively. The defined interest rates fixed for each twelve or thirteen month interest period ranged from 3.50% to 5.24%. Settlement of the swaps was required on a quarterly basis.

Foreign Currency Exposure

Although the U.S. Dollar is Sirona’s reporting currency, its functional currency varies depending on the country of operation. During the periods under review, the U.S. Dollar/Euro exchange rate fluctuated significantly, thereby impacting Sirona’s financial results. In order to manage foreign currency exposures, the Company enters into foreign exchange forward contracts (USD, AUD, and JPY). As with its interest rate swap instruments, the Company enters into forward contracts that are considered to be economic hedges which are not considered hedging instruments under ASC 815.

As of March 31, 2011, these contracts had notional amounts totaling $ 40.5 million. These agreements are relatively short-term (generally six months).

The fair value carrying amount of the Company’s derivative instruments at March 31, 2011 is described in Note 15 Fair Value Measurements.

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The location and amount of gains and losses from the fair value changes of derivative instruments reported in our condensed consolidated statement of income were as follows:


		For the three months ended March 31,						For the six months ended March 31,
		2011			2010			2011		2010
Derivatives Not Designated as Hedging Instruments	Location of (Gain)/Loss Recognized in Income on Derivative	Amount of (Gain)/Loss Recognized in Income on Derivative			Amount of (Gain)/Loss Recognized in Income on Derivative			Amount of (Gain)/Loss Recognized in Income on Derivative		Amount of (Gain)/Loss Recognized in Income on Derivative
		$’000s						$’000s
Interest rate swap contracts	Gain on derivative instruments, net	$	—		$	(2,937	)	$	—		(6,364	)
Foreign exchange contracts	(Gain)/Loss on derivative instruments, net		(1,554	)		1,225			81		3,629

Total		$	(1,554	)	$	(1,712	)	$	81		(2,735	)

15. Fair Value Measurements

The Company applies the provisions of ASC 820, Fair Value Measurements and Disclosures, for assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. ASC 820 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded or disclosed at fair value, the Company considers the principal or most advantageous market in which it would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions, and the credit risk of the Company and counterparties to the arrangement.

ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is available and significant to the fair value measurement. ASC 820 establishes and prioritizes the following three levels of inputs that may be used to measure fair value:

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 2 - Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Inputs that are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability.

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Assets/Liabilities Measured at Fair Value on a Recurring Basis

The following table presents the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2011 and September 30, 2010:


	March 31, 2011
	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Total
			Foreign Exchange
	$’000s
Assets
Cash Equivalents (money market funds)	$	175,218	$	—		$	—	$	175,218
Derivative Assets		—		1,552			—		1,552
Liabilities
Derivative Liabilities	$	—	$	(88	)	$	—	$	(88	)

Total	$	175,218	$	1,464		$	—


	September 30, 2010
	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Total
			Foreign Exchange
	$’000s
Assets
Cash Equivalents (money market funds)	$	141,981	$	—		$	—	$	141,981
Derivative Assets		—		2,015			—		2,015
Liabilities
Derivative Liabilities	$	—	$	(563	)	$	—	$	(563	)

Total	$	141,981	$	1,452		$	—

In the Company’s March 31, 2011 and September 30, 2010 Condensed Consolidated Balance Sheet, derivative assets and derivative liabilities are classified as prepaid expenses and other current assets and accrued liabilities and deferred income, respectively.

The Company did not elect the fair value option for any eligible financial instruments.

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Fair value of financial instruments

Financial instruments consist of cash, cash equivalents, accounts receivable, accounts payable and foreign currency forward contracts. The carrying amounts of cash, cash equivalents, accounts receivable and accounts payable approximate their respective fair values because of the short maturity and nature of these items. The fair value of the foreign currency forward contracts is estimated by obtaining quotes from financial institutions.

16. Segment Reporting

The following tables reflect the results of the Company’s reportable segments under the Company’s management reporting system. The segment performance measure used to monitor segment performance is gross profit (“Segment Performance Measure”) excluding the impact of the acquisition of control of the Sirona business by Sirona Holdings Luxco S.C.A. (“Luxco”), a Luxembourg-based holding entity owned by funds managed by Madison Dearborn Partners (“MDP”), Beecken Petty O’Keefe and management of Sirona, through a leveraged buyout transaction on June 30, 2005 (the “MDP Transaction”) and the Exchange. This measure is considered by management to better reflect the performance of each segment as it eliminates the need to allocate centrally incurred costs and significant purchase accounting impacts that the Company does not believe are representative of the performance of the segments. Furthermore, the Company monitors performance geographically by region. As the Company manages its business on both a product and a geographical basis, U.S. GAAP requires segmental disclosure based on product information.


	Three months ended March 31,						Six months ended March 31,
	2011			2010			2011			2010
	$’000s						$’000s
Revenue External
Dental CAD/CAM Systems	$	77,010		$	66,306		$	160,384		$	140,122
Imaging Systems		72,285			59,535			148,550			130,516
Treatment Centers		41,199			39,857			90,962			83,708
Instruments		23,890			24,196			49,967			50,253

Total		214,384			189,894			449,863			404,599

Electronic center and corporate		353			242			520			360

Total	$	214,737		$	190,136		$	450,383		$	404,959

Revenue Internal
Dental CAD/CAM Systems	$	—		$	—		$	—		$	—
Imaging Systems		3			11			8			15
Treatment Centers		13			8			17			16
Instruments		2,508			2,485			5,216			4,843
Intercompany elimination		(2,524	)		(2,504	)		(5,241	)		(4,874	)

Total		—			—			—			—

Electronic center and corporate		6,327			5,294			12,229			10,431
Intercompany elimination		(6,327	)		(5,294	)		(12,229	)		(10,431	)

Total	$	—		$	—		$	—		$	—

Revenue Total
Dental CAD/CAM Systems	$	77,010		$	66,306		$	160,384		$	140,122
Imaging Systems		72,288			59,546			148,558			130,531
Treatment Centers		41,212			39,865			90,979			83,724
Instruments		26,399			26,681			55,183			55,096

Total		216,909			192,398			455,104			409,473

Electronic center and corporate		6,680			5,536			12,749			10,791

Total	$	223,589		$	197,934		$	467,853		$	420,264

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)


Segment performance measure
Dental CAD/CAM Systems	$	55,159	$	47,498	$	114,195	$	98,434
Imaging Systems		42,353		35,878		88,487		79,176
Treatment Centers		16,426		16,516		38,473		34,676
Instruments		12,011		11,114		24,723		23,423

Total		125,949		111,006		265,878		235,709

Electronic center and corporate		2,682		2,760		5,097		5,186

Total	$	128,631	$	113,766	$	270,975	$	240,895

Depreciation and amortization expense
Dental CAD/CAM Systems	$	1,937	$	1,403	$	3,734	$	2,814
Imaging Systems		1,503		1,257		2,871		2,635
Treatment Centers		1,683		1,608		3,202		3,327
Instruments		807		802		1,570		1,708

Total		5,930		5,070		11,377		10,484

Electronic center and corporate		288		936		568		1,167

Total	$	6,218	$	6,006	$	11,945	$	11,651

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Reconciliation of the results of the segment performance measure to the consolidated statements of operations

The following table and discussion provide a reconciliation of the total results of operations of the Company’s business segments under management reporting to the consolidated financial statements. The differences shown between management reporting and U.S. GAAP for the six months ended March 31, 2011 and 2010 are mainly due to the impact of purchase accounting. Purchase accounting effects are not included in gross profit as the Company does not believe these to be representative of the performance of each segment.

Inter-segment transactions are based on amounts which management believes are approximate to the amounts of transactions with unrelated third parties.


	Three months ended March 31,						Six months ended March 31,
	2011			2010			2011			2010
	$’000s						$’000s
Revenue
Total segments (external)	$	214,384		$	189,894		$	449,863		$	404,599
Electronic center and corporate		353			242			520			360

Consolidated revenue		214,737			190,136			450,383			404,959
Depreciation and amortization
Total segments		5,930			5,070			11,377			10,484
Differences management reporting vs. US GAAP, electronic center and corporate		13,820			15,715			27,580			32,105

Consolidated depreciation and amortization		19,750			20,785			38,957			42,589
Segment performance measure
Total segments		125,949			111,006			265,878			235,709
Differences management reporting vs. US GAAP, electronic center and corporate		(10,260	)		(11,673	)		(19,775	)		(24,006	)

Consolidated gross profit		115,689			99,333			246,103			211,703
Selling, general and administrative expense		70,581			60,354			133,904			120,206
Research and development		14,145			11,690			27,655			23,155
Provision for doubtful accounts and notes receivable		(47	)		72			21			136
Net other operating income		(2,500	)		(3,408	)		(5,000	)		(5,908	)
Foreign currency transaction (gain)/loss, net		(4,336	)		5,049			(5,097	)		4,416
(Gain)/loss on derivative instruments		(1,554	)		(1,712	)		81			(2,735	)
Interest expense, net		929			4,141			1,879			9,343
Other expense/(income)		343			404			(523	)		784

Income before taxes	$	38,128		$	22,743		$	93,183		$	62,306

17. Related parties

Sirona Holdings S.C.A. Luxembourg (“Luxco”)

On July 30, 2010, the Company and Luxco, a significant shareholder of the Company, elected not to renew the advisory services agreement between them that terminated on October 1, 2010. Under the agreement, which became effective October 1, 2005, the Company paid an annual fee to Luxco of €325 (approximately $444 for fiscal year 2010), and Luxco provided to the Company certain advisory services regarding the structure, terms and condition of debt offerings by the Company, financing sources and options, business development and other services.

SIRONA DENTAL SYSTEMS, INC AND SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

In December 2009, Luxco sold 7,100,000 shares pursuant to an underwritten follow-on public offering. The Company incurred $0.4 million of costs pursuant to the terms of a registration rights agreement.

In February 2010, Luxco sold 7,000,000 shares pursuant to an underwritten follow-on public offering. The Company incurred $0.4 million of costs pursuant to the terms of a registration rights agreement.

In March 2011, Luxco sold 4,500,000 shares pursuant to an underwritten follow-on public offering. The Company incurred $0.3 million of costs pursuant to the terms of a registration rights agreement.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) should be read in conjunction with the Condensed Consolidated Financial Statements included elsewhere in this Report and the MD&A included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010. Actual results and the timing of certain events may differ significantly from those projected in such forward-looking statements due to a number of factors, including those set forth in “Results of Operations” in this Item and elsewhere in this Report. All amounts are reported in thousands of U.S. Dollars ($), except as otherwise disclosed.

This report contains forward-looking statements that involve risk and uncertainties. All statements, other than statements of historical facts, included in this report regarding the Company, its financial position, products, business strategy and plans and objectives of management of the Company for future operations, are forward-looking statements. When used in this report, words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “objectives,” “plans” and similar expressions, or the negatives thereof or variations thereon or comparable terminology as they relate to the Company, its products or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of various factors, including, but not limited to, those contained in the “Risk Factors” set forth in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2010. All forward looking statements speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligation to update or revise forward-looking statements which may be made to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events other than required by law.

Overview

Sirona Dental Systems Inc. (“Sirona”, the “Company”, “we”, “us”, and “our” refer to Sirona Dental Systems, Inc. and its consolidated subsidiaries and their predecessors) is the leading manufacturer of high-quality, technologically advanced dental equipment, and is focused on developing, manufacturing and marketing innovative systems and solutions for dentists around the world. The Company is uniquely positioned to benefit from several trends in the global dental industry, such as technological innovation, increased use of CAD/CAM systems in restorative dentistry, the shift to digital imaging, favorable demographic trends and growing patient focus on dental health and cosmetic appearance. The Company has its headquarters in Long Island City, New York and its largest facility in Bensheim, Germany.

Sirona has a long tradition of innovation in the dental industry. The Company introduced the first dental electric drill approximately 130 years ago, the first dental X-ray unit approximately 100 years ago, the first dental computer-aided design/computer-aided manufacturing (“CAD/CAM”) system 25 years ago, and numerous other significant innovations in dentistry. Sirona continues to make significant investments in research and development, and its track record of innovative and profitable new products continues today with numerous product launches including: the SINIUS treatment center (launched in March 2011), the Orthophos XG3D (launched in October 2010), the inEOS Blue (launched in January 2010), the Galileos and CEREC combination (launched in September 2009), the CEREC AC unit (launched in January 2009), the Galileos Compact 3D imaging system (launched in July 2008), the TENEO treatment center (launched in July 2008) and the CAD/CAM milling unit MC XL (launched in fiscal year 2007).

Sirona manages its business on both a product and geographic basis and has four segments: Dental CAD/CAM Systems, Imaging Systems, Treatment Centers, and Instruments. Sirona has the broadest product portfolio in the industry, and is capable of fully outfitting and integrating a dental practice. Products from each category are marketed in all geographical sales regions.

The Company’s business has grown substantially over the past five years, driven by numerous high-tech product introductions, a continued expansion of its global sales and service infrastructure, strong relationships with key distribution partners, namely Patterson and Henry Schein, and an international dealer network. Patterson and Henry Schein accounted for 28% and 18%, respectively, of Sirona’s global revenues for the six months ended March 31, 2011.

The U.S. market is the largest individual market for Sirona, followed by Germany. Between fiscal years 2004 and 2010, the Company increased U.S. revenues from $88.2 million to $239.5 million, driven by innovative products, particularly in the CAD/CAM and Imaging segments and the Exchange. Patterson made a payment of $100 million to Sirona in July 2005 in exchange for the exclusive distribution rights for CAD/CAM products in the U.S. and Canada until 2017 (the “Patterson exclusivity payment”). The amount received was recorded as deferred income and is being recognized on a straight-line basis that commenced at the beginning of the extension of the exclusivity period in fiscal year 2008.

In addition to strong U.S. market growth, Sirona has pursued expansion in non-U.S. and non-German markets. Between fiscal years 2004 and 2010, the Company increased revenues in non-U.S. and non-German markets from $190.9 million to $382.4 million. To support this growth, Sirona expanded its local presence and distribution channels by establishing sales and service locations in Japan, Australia, China, Korea, Brazil, Italy, France, and the UK. The expansion helped to increase market share but also contributed to higher SG&A expenses. Due to the international nature of the Company’s business, movements in global foreign exchange rates have a significant effect on financial results.

The weak global economy in 2009 resulted in a challenging environment for selling dental technology, which impacted Sirona’s revenue and financial performance. While the global economy improved in 2010, it did not fully recover and we continued to experience economic headwinds in fiscal year 2010. Despite these headwinds, Sirona increased revenues by 7.9% constant currency in fiscal year 2010, with strong growth in our Imaging segment driven by our Galileos 3D imaging system. In fiscal year 2010, our net income benefited from this revenue growth, but also from margin expansion, expense management initiatives, and debt reduction. Our targeted cost-saving actions were on plan, and we started reinvesting some of these cost savings in the second half of fiscal year 2010.

The positive trends from fiscal year 2010 strengthened during the first six months of fiscal year 2011. This development is driven by robust demand for our technologically advanced product portfolio, continued investment in our global sales and service infrastructure, and new product developments. Revenues were particularly strong in international markets during the first half of fiscal year 2011, up 21.2% on a constant currency basis. Our net income benefited from strong sales growth, margin expansion, and debt reduction. The biennial International Dental Show (“IDS”) in Cologne at the end of March 2011 was encouraging, and we expect to benefit from the strong interest in our product portfolio going forward.

Significant Factors that Affect Sirona’s Results of Operations

The MDP Transaction and the Exchange

On June 30, 2005, Sirona Holdings Luxco S.C.A. (“Luxco”), a Luxembourg-based holding entity owned by funds managed by Madison Dearborn Partners, Beecken Petty O’Keefe, management and employees of Sirona, obtained control over the Sirona business. The transaction was effected by using new legal entities, Sirona Holding GmbH (formerly Blitz 05-118 GmbH) and its wholly owned subsidiary Sirona Dental Services GmbH, to acquire 100% of the interest in Sirona Dental Systems Beteiligungs- und Verwaltungs GmbH, the former parent of the Sirona business through a leveraged buy-out transaction (the “MDP Transaction”).

The assets and liabilities acquired in the MDP Transaction and the Exchange were partially stepped up to fair value, and a related deferred tax liability was recorded. The excess of the total purchase price over the fair value of the net assets acquired, including IPR&D, which were expensed at the date of closing of the MDP Transaction and the Exchange, was allocated to goodwill and is subject to periodic impairment testing.

Sirona’s cost of goods sold, research and development, selling, general and administrative expense and operating result have been and will continue to be materially affected by depreciation and amortization costs resulting from the step-up to fair value of Sirona’s assets and liabilities.

Fluctuations in U.S. Dollar/Euro Exchange Rate

Although the U.S. Dollar is Sirona’s reporting currency, its functional currencies vary depending on the country of operation. For the six months ended March 31, 2011, approximately 47% of Sirona’s revenue and approximately 71% of its expenses were in Euro. During the periods under review, the U.S. Dollar/Euro exchange rate has fluctuated significantly, thereby impacting Sirona’s financial results. Between October 1, 2009 and March 31, 2011, the U.S. Dollar/Euro exchange rate used to calculate items included in Sirona’s financial statements varied from a low of $1.1919 to a high of $1.5121. Although Sirona does not apply hedge accounting, Sirona has entered into foreign exchange forward contracts to manage foreign currency exposure. As of March 31, 2011, these contracts had notional amounts totaling $40.5 million. As these agreements are relatively short-term (generally six months), continued fluctuation in the U.S. Dollar/Euro exchange rate could materially affect Sirona’s results of operations.

Certain revenue information above and under “Results of Operations” below is presented on a constant currency basis. This information is a non-GAAP financial measure. Sirona supplementally presents revenue on a constant currency basis because it believes this information facilitates a comparison of Sirona’s operating results from period to period without regard to changes resulting solely from fluctuations in currency rates. Sirona calculates constant currency revenue growth by comparing current period revenues to prior period revenues with both periods converted at the U.S. Dollar/Euro average

foreign exchange rate for each month of the current period. The average exchange rate for the six months ended March 31, 2011, was $1.36368 and varied from $1.40040 to $1.32171. For the three and six months ended March 31, 2010, an average quarterly exchange rate converting Euro denominated revenues into U.S. Dollars of $1.38559 and $1.43182, respectively, was applied.

Loans made to Sirona under the Senior Facilities Agreement entered into on November 22, 2006 are denominated in the functional currency of the respective borrowers. See “Liquidity and Capital Resources” for a discussion of our Senior Facilities Agreement. However, intra-group loans are denominated in the functional currency of only one of the parties to the loan agreements. Where intra-group loans are of a long-term investment nature, the potential non-cash fluctuations in exchange rates are reflected within other comprehensive income. These fluctuations may be significant in any period due to changes in the exchange rates between the Euro and the U.S. Dollar.

Fluctuations in Quarterly Operating Results

Sirona’s quarterly operating results have varied in the past and are likely to vary in the future. These variations result from a number of factors, many of which are substantially outside its control, including:

•

the timing of new product introductions by us and our competitors;

•

timing of industry tradeshows, particularly the International Dental Show;

•

changes in relationships with distributors;

•

developments in government reimbursement policies;

•

changes in product mix;

•

our ability to supply products to meet customer demand;

•

fluctuations in manufacturing costs;

•

tax incentives;

•

currency fluctuations; and

•

general economic conditions, as well as those specific to the healthcare industry and related industries.

Due to the variations which Sirona has experienced in its quarterly operating results, it does not believe that period-to-period comparisons of results of operations of Sirona are necessarily meaningful or reliable as indicators of future performance.

Effective Tax Rate

Results of Operations

Three Months Ended March 31, 2011 Compared to Three Months Ended March 31, 2010

Revenue

Revenue for the three months ended March 31, 2011 was $214.7 million, an increase of $24.6 million, or 12.9%, as compared with the three months ended March 31, 2010. On a constant currency basis, adjusting for the fluctuations in the U.S. Dollar/Euro exchange rate, total revenue increased by 14.0%. By segment, Imaging Systems increased 21.4% (up 22.2% on a constant currency basis), CAD/CAM Systems increased 16.1% (up 17.0% on a constant currency basis), Treatment Centers increased 3.4% (up 4.8% on a constant currency basis), and Instruments decreased 1.3% (flat on a constant currency basis).

We were able to grow our revenues due to solid demand for our innovative products, and we continue to benefit from our global sales and service infrastructure. Our products enable dental professionals to improve their clinical results and to increase the profitability of their practices. Our presence at the IDS at the end of March 2011 demonstrated our innovative strength and the breadth of our products.

Imaging Systems revenues showed a strong increase driven by robust demand, particularly for our Orthophos product line. Growth was strong in Europe, led by Germany. CAD/CAM Systems revenues benefited from robust growth in many international markets. Treatment Center revenue was driven by larger volume projects in the economy product line in non-EU international markets, particularly the Middle East, China, and Russia. Instrument revenues were flat year over year with good unit sales growth, leading to gross profit margin improvement, due to positive economies of scale effects.

Revenue in the U.S. for the three months ended March 31, 2011 was up 2.9% compared to the prior year period. Revenue growth was mainly driven by the CAD/CAM Systems segment. Revenue outside the U.S. increased by 17.5%. On a constant currency basis, adjusting for the fluctuations in the U.S. Dollar/Euro exchange rate, these revenues increased by 19.0%. Revenue growth was particularly strong in Europe, led by Germany, as well as in Asia-Pacific, Russia, and the Middle East.

Revenue growth on a constant currency basis was mainly volume driven.

Cost of Sales

Cost of sales for the three months ended March 31, 2011 was $99.0 million, an increase of $8.2 million, or 9.1%, as compared with the three months ended March 31, 2010. Gross profit as a percentage of revenue was 53.9% compared to 52.2% in the prior year period. Cost of sales included amortization and depreciation expense resulting from the step-up to fair values of tangible and intangible assets of $12.5 million as well as non-cash share-based compensation expense of $0.04 million for the three months ended March 31, 2011 compared to amortization and depreciation expense resulting from the step-up to fair values of tangible and intangible assets of $14.2 million and non-cash share-based compensation expense of $0.03 million for the three months ended March 31, 2010. Excluding these amounts, cost of sales as a percentage of revenue was 40.3% for the three months ended March 31, 2011 compared with 40.2% for the three months ended March 31, 2010, and therefore gross profit as a percentage of revenue was 59.7%, unchanged from the prior year period.

Selling, General and Administrative

For the three months ended March 31, 2011, SG&A expense was $70.6 million, an increase of $10.2 million, or 16.9%, as compared with the three months ended March 31, 2010. The increase in SG&A expense is mainly driven by expenses in connection with the biennial IDS, product launch expenses, increased revenues, as well as investments in sales and service infrastructure in international markets. SG&A expense included amortization and depreciation resulting from the step-up to fair values of tangible and intangible assets of $0.7 million as well as non-cash share-based compensation expense in the amount of $2.5 million for the three months ended March 31, 2011, compared with $0.8 million and $4.0 million, respectively, for the three months ended March 31, 2010. Excluding these amounts, as a percentage of revenue, SG&A expense increased to 31.4% for the three months ended March 31, 2011, as compared with 29.2% for the three months ended March 31, 2010.

Research and Development

R&D expense for the three months ended March 31, 2011, was $14.1 million, an increase of $2.5 million, or 21.0%, as compared with the three months ended March 31, 2010. The increase of R&D expense was primarily driven by the timing of new product launches.

R&D expense included non-cash share-based compensation expense in the amount of $0.04 million for the three months ended March 31, 2011, compared with $0.1 million for the three months ended March 31, 2010. Excluding this amount, as a percentage of revenue, R&D expense increased to 6.6% for the three months ended March 31, 2011, compared to 6.1% for the three months ended March 31, 2010.

Net Other Operating Income

Net other operating income for the three months ended March 31, 2011 and 2010 was $2.5 million and $3.4 million, respectively. In both periods, net other operating income included $2.5 million of income resulting from the amortization of the deferred income relating to the Patterson exclusivity payment. In the three months ended March 31, 2010, net other operating income included a gain from the sale of a subsidiary in Italy of $0.9 million.

(Gain)/Loss on Foreign Currency Transactions

Gain on foreign currency transactions for the three months ended March 31, 2011 amounted to $4.3 million compared to a loss of $5.0 million for the three months ended March 31, 2010. For the three months ended March 31, 2011, the gain included an unrealized non-cash foreign currency gain of $3.9 million on the U.S. Dollar denominated deferred income from the translation adjustment of Patterson’s exclusivity payment and an unrealized non-cash foreign currency gain on the U.S. Dollar denominated short term intra-group loans to our Austrian entity of $4.3 million. Excluding these amounts, foreign currency transactions for the three months ended March 31, 2011 resulted in a loss of $3.9 million.

The loss for the three months ended March 31, 2010 included an unrealized non-cash foreign currency loss of $5.1 million on the U.S. Dollar denominated deferred income from the translation adjustment of Patterson’s exclusivity payment, as well as a non-cash unrealized foreign currency loss on the U.S. Dollar denominated short term intra-group loans to our Austrian entity of $4.4 million. Excluding these amounts, foreign currency transactions for the three months ended March 31, 2010 resulted in a gain of $4.5 million.

Gain on Derivative Instruments

The gain on derivative instruments for the three months ended March 31, 2011, amounted to $1.6 million compared to a gain of $1.7 million for the three months ended March 31, 2010. For the three months ended March 31, 2011, the gain included an unrealized non-cash gain on foreign currency hedges of $1.6 million. The gain for the three months ended March 31, 2010, included an unrealized non-cash gain of $2.9 million on interest swaps, as well as a non-cash loss on foreign currency hedges of $1.2 million.

Interest Expense

Net interest expense for the three months ended March 31, 2011, was $0.9 million, compared to $4.1 million for the three months ended March 31, 2010. This decrease resulted from lower interest rates and lower overall debt levels.

Income Tax Provision

For the three months ended March 31, 2011 and 2010, Sirona recorded a profit before income taxes of $38.1 million and $22.7 million, respectively. The estimated effective tax rate applied for these periods was 22% and 20%, respectively, compared to an actual effective tax rate of 20.6% in fiscal year 2010. The income tax provision for the three months ended March 31, 2011 and 2010, was $8.4 million and $4.5 million, respectively. The estimated effective tax rate is primarily driven by the expected mix of earnings across different countries.

Net Income

Net income for the three months ended March 31, 2011 was $29.7 million, an increase of $11.5 million, as compared with the three months ended March 31, 2010. Major influencing factors on net income were the increase in revenues, lower interest and debt levels, and the lower amortization of assets acquired in past business combinations, partially offset by the increase in operating expenses and a higher estimated effective tax rate. Net income for the three months ended March 31, 2011 included amortization and depreciation expense resulting from the step-up to fair values of intangible and tangible assets related to past business combinations (i.e. the Exchange and the MDP Transaction - deal related amortization and depreciation) of $13.2 million ($10.3 million net of tax), unrealized, non-cash foreign currency gain on the deferred income from the Patterson exclusivity payment of $3.9 million ($3.0 million net of tax), and gain on the revaluation of short-term intra-group loans of $4.3 million ($3.4 million net of tax).

Sirona’s net income for the three months ended March 31, 2010 included deal related amortization and depreciation of assets acquired in past business combinations of $15.1 million ($12.1 million net of tax), currency revaluation losses on the Patterson exclusivity payment of $5.1 million ($4.1 million after tax), and a loss on the revaluation of short-term intra-group loans of $4.4 million ($3.5 million net of tax).

Share-based compensation expense was $2.6 million ($2.0 million net of tax) in the second quarter of 2011 compared to $4.1 million ($3.3 million net of tax) in the prior year period.

Six Months Ended March 31, 2011 Compared to Six Months Ended March 31, 2010

Revenue

Revenue for the six months ended March 31, 2011 was $450.4 million, an increase of $45.4 million, or 11.2%, as compared with the six months ended March 31, 2010. On a constant currency basis, adjusting for the fluctuations in the U.S. Dollar/Euro exchange rate, total revenue increased by 14.9%. By segment, CAD/CAM Systems increased 14.5% (up 17.6% on a constant currency basis), Imaging Systems increased 13.8% (up 16.3% on a constant currency basis), Treatment Centers increased 8.6% (up 14.0% on a constant currency basis), and Instruments decreased 0.5% (up 4.3% on a constant currency basis).

We were able to grow our revenues in all segments due to solid demand for our innovative products, and we continue to benefit from our global sales and service infrastructure. Our products enable dental professionals to improve their clinical results and to increase the profitability of their practices.

CAD/CAM Systems revenues were particularly strong in Europe and benefited from a trade-up program in Germany. The increase in Imaging Systems revenues showed in all regions and was driven by strong interest in our 2D and 3D panoramic systems. Treatment Center revenues showed a strong increase in all product lines. Growth was particularly driven by our European and Asia-Pacific markets. Instrument revenues were up, benefiting from high-volume projects in several international markets.

Revenue in the U.S. for the six months ended March 31, 2011 was up 1.8% compared to the prior year period. Revenue outside the U.S. increased by 15.5%. On a constant currency basis, adjusting for the fluctuations in the U.S. Dollar/Euro exchange rate, these revenues increased by 21.2%. Revenue growth was particularly strong in Europe, led by Germany, as well as in the Asia-Pacific and Middle East markets.

Revenue growth on a constant currency basis was mainly volume driven.

Cost of Sales

Cost of sales for the six months ended March 31, 2011 was $204.3 million, a increase of $11.0 million, or 5.7%, as compared with the six months ended March 31, 2010. Gross profit as a percentage of revenue was 54.6% compared to 52.3% in the prior year period. Cost of sales included amortization and depreciation expense resulting from the step-up to fair values of tangible and intangible assets of $24.9 million as well as non-cash share-based compensation expense of $0.1 million for the six months ended March 31, 2011 compared to amortization and depreciation expense resulting from the step-up to fair values of tangible and intangible assets of $29.2 million and non-cash share-based compensation expense of $0.1 million for the six months ended March 31, 2010. Excluding these amounts, cost of sales as a percentage of revenue was 39.8% for the six months ended March 31, 2011 compared with 40.5% for the six months ended March 31, 2010, and therefore gross profit as a percentage of revenue was 60.2% compared to 59.5% in the prior year period. The expansion in the gross profit margin was mainly due to product and regional mix and showed in all segments, except for a slight decrease in the Imaging segment.

Selling, General and Administrative

For the six months ended March 31, 2011, SG&A expense was $133.9 million, a increase of $13.7 million, or 11.4%, as compared with the six months ended March 31, 2010. The increase in the absolute SG&A expense is mainly driven by increased revenues, investments in sales and service infrastructure in international markets, as well as expenses in connection with the biennial IDS. SG&A expense included amortization and depreciation resulting from the step-up to fair values of tangible and intangible assets of $1.3 million as well as non-cash share-based compensation expense in the amount of $4.3 million for the six months ended March 31, 2011, compared with $1.7 million and $7.9 million, respectively, for the six months ended March 31, 2010. Excluding these amounts, as a percentage of revenue, SG&A expense increased to 28.4% for the six months ended March 31, 2011, as compared with 27.3% for the six months ended March 31, 2010.

Research and Development

R&D expense for the six months ended March 31, 2011, was $27.7 million, an increase of $4.5 million, or 19.4%, as compared with the six months ended March 31, 2010. The increase of R&D expense was primarily driven by the timing of new product launches, partially in connection with the IDS.

R&D expense included non-cash share-based compensation expense in the amount of $0.1 million for the six months ended March 31, 2011, compared with $0.1 million for the six months ended March 31, 2010. Excluding this amount, as a percentage of revenue, R&D expense increased to 6.1% for the six months ended March 31, 2011, compared to 5.7% for the six months ended March 31, 2010.

Net Other Operating Income

Net other operating income for the six months ended March 31, 2011 and 2010 was $5.0 million and $5.9 million, respectively. In both periods, net other operating income included $5.0 million of income resulting from the amortization of the deferred income relating to the Patterson exclusivity payment. For the three and six months ended March 31, 2010, net other operating income included a gain from the sale of a subsidiary in Italy of $0.9 million.

(Gain)/Loss on Foreign Currency Transactions

Gain on foreign currency transactions for the six months ended March 31, 2011 amounted to $5.1 million compared to a loss of $4.4 million for the six months ended March 31, 2010. For the six months ended March 31, 2011, the gain included an unrealized non-cash foreign currency gain of $2.5 million on the U.S. Dollar denominated deferred income from the translation adjustment of Patterson’s exclusivity payment and an unrealized non-cash foreign currency gain on the U.S. Dollar denominated short term intra-group loans to our Austrian entity of $3.0 million. Excluding these amounts, foreign currency transactions for the six months ended March 31, 2011 resulted in a loss of $0.4 million.

The loss for the six months ended March 31, 2010 included an unrealized non-cash foreign currency loss of $6.5 million on the U.S. Dollar denominated deferred income from the translation adjustment of Patterson’s exclusivity payment, as well as a non-cash unrealized foreign currency loss on the U.S. Dollar denominated short term intra-group loans to our Austrian entity of $5.7 million. Excluding these amounts, foreign currency transactions for the six months ended March 31, 2010 resulted in a gain of $7.8 million.

Loss/(Gain) on Derivative Instruments

The loss on derivative instruments for the six months ended March 31, 2011, amounted to $0.1 million compared to a gain of $2.7 million for the six months ended March 31, 2010. For the six months ended March 31, 2011, the loss included an unrealized non-cash loss on foreign currency hedges of $0.1 million. The gain for the six months ended March 31, 2010, included an unrealized non-cash gain of $6.3 million on interest swaps, as well as a non-cash loss on foreign currency hedges of $3.6 million.

Interest Expense

Net interest expense for the six months ended March 31, 2011, was $1.9 million, compared to $9.3 million for the six months ended March 31, 2010. This decrease resulted from lower interest rates and lower overall debt levels.

Income Tax Provision

For the six months ended March 31, 2011 and 2010, Sirona recorded a profit before income taxes of $93.2 million and $62.3 million, respectively. The estimated effective tax rate applied for these periods was 22% and 20%, respectively, compared to an actual effective tax rate of 20.6% in fiscal year 2010. The income tax provision for the six months ended March 31, 2011 and 2010, was $20.5 and $12.5 million, respectively. The estimated effective tax rate is primarily driven by the expected mix of earnings across different countries.

Net Income

Net income for the six months ended March 31, 2011 was $72.7 million, an increase of $22.8 million, as compared with the six months ended March 31, 2010. Major influencing factors on net income were the increase in revenues, lower interest and debt levels, and the lower amortization of assets acquired in past business combinations, partially offset by the increase in operating expenses and a higher estimated effective tax rate. Net income for the six months ended March 31, 2011 included amortization and depreciation expense resulting from the step-up to fair values of intangible and tangible assets related to past business combinations (i.e. the Exchange and the MDP Transaction - deal related amortization and depreciation) of $26.3 million ($20.5 million net of tax), unrealized, non-cash foreign currency gain on the deferred income from the Patterson exclusivity payment of $2.5 million ($1.9 million net of tax), and gain on the revaluation of short-term intra-group loans of $3.0 million ($2.3 million net of tax).

Sirona’s net income for the six months ended March 31, 2010 included deal related amortization and depreciation of assets acquired in past business combinations of $31.1 million ($24.9 million net of tax), currency revaluation losses on the Patterson exclusivity payment of $6.5 million ($5.2 million after tax), a gain on interest swaps of $6.3 million ($5.0 million net of tax), and a loss on the revaluation of short-term intra-group loans of $5.7 million ($4.6 million net of tax).

Share-based compensation expense was $4.5 million ($3.5 million net of tax) in the first six months of fiscal year 2011 compared to $8.0 million ($6.4 million net of tax) in the prior year period.

Liquidity and Capital Resources

Historically, Sirona’s principal uses of cash, apart from operating requirements, including research and development expenses, have been for interest payments, debt repayment and acquisitions. Operating capital expenditures are approximately equal to operating depreciation (excluding any effects from the increased amortization and depreciation expense resulting from the step-up to fair values of Sirona’s and Schick’s assets and liabilities required under purchase accounting). Sirona believes that its operating cash flows and available cash (including restricted cash) will be sufficient to fund its working capital needs, research and development expenses, and anticipated capital expenditures for the foreseeable future. With its expected operating cash flows and its access to capital markets, Sirona also believes it will be able to comply with its repayment obligations for the final senior debt tranche due in November 2011.

The Senior Facilities Agreement contains restrictive covenants that limit Sirona’s ability to make loans, make investments (including in joint ventures), incur additional indebtedness, make acquisitions or pay dividends, subject to agreed exceptions. The Company has agreed to certain financial debt covenants in relation to the financing. The covenants stipulate that the Company must maintain certain ratios in respect of interest payments and defined earnings measures. If the Company breaches any of the covenants, the loans will be become repayable on demand.

The financial covenants require that the Company maintain a debt coverage ratio (“Debt Cover Ratio”) of consolidated total net debt to consolidated adjusted EBITDA (“Consolidated Adjusted EBITDA”) of no more than 2.50 to 1, and a cash interest coverage ratio (“Cash Interest Cover Ratio”) of consolidated adjusted EBITDA to cash interest costs of 4.00 to 1 or greater. The Company is required to test its ratios as of September 30 and March 31. As calculated in accordance with the Senior Facilities Agreement, the following table presents the Company’s actual Debt Cover Ratio and Cash Interest Cover Ratio, and their respective components, for required testing periods in fiscal years 2011 and 2010:


	LTM March 31 2011		Year Ended September 30 2010		LTM March 31 2010
	$’000s
Consolidated Total Net Debt	$	82.3	$	119.2	$	205.2
Cash Interest Costs	$	4.4	$	6.9	$	11.1
Consolidated Adjusted EBITDA	$	232.5	$	233.7	$	248.1
Debt Cover Ratio		0.35		0.51		0.83
as set by covenants (less than or equal to)		2.50		2.50		2.50
Cash Interest Cover Ratio		53.44		33.93		22.39
as set by covenants (greater than or equal to)		4.00		4.00		4.00

Cash Flows


	Six months ended March 31,
	2011			2010
	$’000s
Net cash provided by operating activities	$	54,617		$	74,810
Net cash used in investing activities		(23,824	)		(7,718	)
Net cash provided by/(used in) financing activities		8,357			(73,918	)

Increase in cash during the period	$	39,150		$	(6,826	)

Net Cash Provided by Operating Activities

Net cash provided by operating activities represents net cash from operations, returns on investments, and payments for interest and taxation.

Net cash provided by operating activities was $54.6 million for the six months ended March 31, 2011 compared to $74.8 million for the six months ended March 31, 2010. The primary contributing factor to the decrease in cash provided by operating cash flows in the six months ended March 31, 2011 was an increase in working capital driven by the overall increase in business, which was strongest at the end of the quarter, as well as the expansion of our global sales and service infrastructure.

Net Cash Used in Investing Activities

Net cash used in investing activities represents cash used for capital expenditures in the normal course of operating activities, financial investments, acquisitions and long-lived asset disposals. The primary contributors to the investing cash outflow in the six months ended March 31, 2011 were capital expenditures in the course of normal operating activities as well as construction of the Center of Innovation in Bensheim, Germany. For the six months ended March 31, 2010, net cash used in investing activities represented capital expenditures in the course of normal operating activities, partly offset by proceeds from the sale of a subsidiary in Italy.

Net Cash Provided by / (Used in) Financing Activities

Net cash provided by financing activities was $8.4 million for the six months ended March 31, 2011, compared to net cash used in financing activities of $73.9 million for the six months ended March 31, 2010. Net cash provided by financing activities in the six months ended March 31, 2011 results from proceeds and tax-related benefits from exercises of options previously granted in the Company’s stock-based compensation activities. Net cash used in financing activities in the six months ended March 31, 2010 primarily relates to the early repayment of senior debt that was originally due in November 2010 eight months ahead of schedule, partly offset by proceeds and tax-related benefits of exercises of options previously granted in the Company’s stock-based compensation activities.

Capital Resources

Senior Facilities Agreement

On November 22, 2006, Sirona Dental Systems, Inc. entered into a senior facilities agreement (the “Senior Facilities Agreement”) as original guarantor, with Schick Technologies, Inc., a New York company and wholly owned subsidiary of Sirona (“Schick NY”), as original borrower and original guarantor, with Sirona Dental Systems GmbH, as original borrower and original guarantor, with Sirona Dental Services GmbH, as original borrower and original guarantor and with Sirona Dental Systems LLC, Sirona Holding GmbH (subsequently merged with Sirona Dental Services GmbH) and Sirona Immobilien GmbH as original guarantors. Initial borrowings under the Senior Facilities Agreement plus excess cash were used to retire the outstanding borrowings under the Company’s previous credit facilities.

The Senior Facilities Agreement includes: (1) a term loan A1 in an aggregate principal amount of $150 million (the “tranche A1 term loan”) available to Sirona’s subsidiary, Schick NY, as borrower; (2) a term loan A2 in an aggregate principal amount of Euro 275 million (the “tranche A2 term loan”) available to Sirona’s subsidiary, Sirona Dental Services GmbH, as borrower; and (3) a $150 million revolving credit facility available to Sirona Dental Systems GmbH, Schick NY and Sirona Dental Services GmbH, as initial borrowers. The revolving credit facility is available for borrowing in Euro, U.S. Dollars, Yen or any other freely available currency agreed to by the facility agent. The facilities are made available on an unsecured basis. Subject to certain limitations, each European guarantor guarantees the performance of each European borrower, except itself, and each U.S. guarantor guarantees the performance of each U.S. borrower, except itself. There are no cross-border guarantees since all guarantees are by entities that have the same functional currency as the currency in which the respective guaranteed borrowing is denominated.

Each of the senior term loans has a five year maturity and is to be repaid in three annual installments beginning on November 24, 2009 and ending on November 24, 2011. Of the amounts borrowed under the term loan facilities, 15% was due on November 24, 2009, 15% was due on November 24, 2010 and 70% is due on November 24, 2011. The senior debt repayment tranche originally scheduled for November 24, 2009 was prepaid on May 11, 2009 in the amount of $78.6 million,

and the senior debt repayment tranche originally scheduled for November 24, 2010 was prepaid on March 31, 2010 in the amount of $78.1 million. At the Company’s current Debt Cover Ratio, the facilities bear interest of Euribor, for Euro-denominated loans, and Libor for the other loans, plus a margin of 45 basis points for both.

The Senior Facilities Agreement contains restrictive covenants that limit Sirona’s ability to make loans, make investments (including in joint ventures), incur additional indebtedness, make acquisitions or pay dividends, subject to agreed exceptions. The Company has agreed to certain financial debt covenants in relation to the financing. The covenants stipulate that the Company must maintain certain ratios in respect of interest payments and defined earnings measures. If the Company breaches any of the covenants, the loans will be become repayable on demand.

Debt issuance costs of $5.6 million were incurred in relation to the new financing and were capitalized as deferred charges.

Other Financial Data


	Three months ended March 31,				Six months ended March 31,
	2011		2010		2011		2010
	$’000s				$’000s
Net income attributable to Sirona Dental Systems, Inc.	$	29,312	$	17,539	$	71,704	$	48,714
Net interest expense		929		4,141		1,879		9,343
Provision for income taxes		8,388		4,548		20,500		12,461
Depreciation		6,218		5,307		11,945		10,929
Amortization		13,532		15,503		27,012		31,660

EBITDA	$	58,379	$	47,038	$	133,040	$	113,107

EBITDA is a non-GAAP financial measure that is reconciled to net income, its most directly comparable U.S. GAAP measure, in the accompanying financial tables. EBITDA is defined as net earnings before interest, taxes, depreciation, and amortization. Sirona’s management utilizes EBITDA as an operating performance measure in conjunction with U.S. GAAP measures, such as net income and gross margin calculated in conformity with U.S. GAAP. EBITDA should not be considered in isolation or as a substitute for net income prepared in accordance with U.S. GAAP. There are material limitations associated with making the adjustments to Sirona’s earnings to calculate EBITDA and using this non-GAAP financial measure. For instance, EBITDA does not include:

•

interest expense, and because Sirona has borrowed money in order to finance its operations, interest expense is a necessary element of its costs and ability to generate revenue;

•

depreciation and amortization expense, and because Sirona uses capital and intangible assets, depreciation and amortization expense is a necessary element of its costs and ability to generate revenue; and

•

tax expense, and because the payment of taxes is part of Sirona’s operations, tax expense is a necessary element of costs and impacts Sirona’s ability to operate.

In addition, other companies may define EBITDA differently. EBITDA, as well as the other information in this filing, should be read in conjunction with Sirona’s consolidated financial statements and footnotes.

In addition to EBITDA, the accompanying financial tables also set forth certain supplementary information that Sirona believes is useful for investors in evaluating Sirona’s underlying operations. This supplemental information includes gains/losses recorded in the periods presented which relate to the early extinguishment of debt, share based compensation, revaluation of the U.S. Dollar-denominated exclusivity payment and borrowings where the functional currency is the Euro, and the Exchange. Sirona’s management believes that these items are either nonrecurring or non-cash in nature, and should be considered by investors in assessing Sirona’s financial condition, operating performance and underlying strength.

Sirona’s management uses EBITDA together with this supplemental information as an integral part of its reporting and planning processes and as one of the primary measures to, among other things:

(i)

monitor and evaluate the performance of Sirona’s business operations;

(ii)

facilitate management’s internal comparisons of the historical operating performance of Sirona’s business operations;

(iii)

facilitate management’s external comparisons of the results of its overall business to the historical operating performance of other companies that may have different capital structures and debt levels;

(iv)

analyze and evaluate financial and strategic planning decisions regarding future operating investments; and

(v)

plan for and prepare future annual operating budgets and determine appropriate levels of operating investments.

Sirona believes that EBITDA and the supplemental information provided is useful to investors as it provides them with disclosures of Sirona’s operating results on the same basis as that used by Sirona’s management.

Supplemental Information


	Three months ended March 31,					Six months ended March 31,
	2011			2010		2011			2010
	$’000s					$’000s
Share-based compensation	$	2,568		$	4,109	$	4,479		$	8,048
Unrealized, non-cash (gain)/loss on revaluation of the carrying value of the $-denominated exclusivity fee		(3,878	)		5,099		(2,470	)		6,451
Unrealized, non-cash (gain)/loss on revaluation of the carrying value of short-term intra-group loans		(4,347	)		4,404		(3,001	)		5,671

	$	(5,657	)	$	13,612	$	(992	)	$	20,170

Recent Accounting Pronouncements Not Yet Adopted

Please see Note 2 to the unaudited condensed consolidated financial statements for any discussions of recently issued accounting pronouncements that have not yet been adopted.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes to the Company’s market risk as reported under Part II, Item 7A in its Annual Report on Form 10-K for the fiscal year ended September 30, 2010.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer (principal executive officer) and chief financial officer (principal financial officer), evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), as of March 31, 2011. Based upon this evaluation, our chief executive officer and chief financial officer concluded that, as of March 31, 2011, the Company’s disclosure controls and procedures are effective. Our disclosure controls and procedures are designed to ensure that information relating to the Company, including our consolidated subsidiaries, that is required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in Commission’s rules and forms, and is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

No change in our internal control over financial reporting (as defined in rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended March 31, 2011, has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II

ITEM 1.

LEGAL PROCEEDINGS

There are currently no material legal proceedings pending.

ITEM 1A.

RISK FACTORS

There are no material changes from risk factors as previously disclosed by the Company in Part I, Item 1A of its Annual Report on Form 10-K for the fiscal year ended September 30, 2010, except as follows:

The earthquake and tsunami in Japan may affect the supply of certain components for our devices.

As a result of the recent earthquake and tsunami as well as their aftermath in Japan, the lead time for certain components for our devices may increase and thus adversely affect our operations and financial results.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

(REMOVED AND RESERVED)

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

The following Exhibits are included in this report:


Exhibit No.		Item Title

10.1#		Amendment to Consolidated and Restated Amendment to Distributorship Agreement, dated as of May 3, 2011, between Patterson Companies, Inc. and Sirona Dental Systems GmbH.

31.1		Certification of Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Section 1350 Certification of Chief Executive Officer.

32.2		Section 1350 Certification of Chief Financial Officer.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB		XBRL Extension Labels Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

#	A request for confidentiality has been filed for certain portions of the indicated document. Confidential portions have been omitted and filed separately with the Securities and Exchange Commission as required by Rule 24b-2 promulgated under the Securities Exchange Act of 1934.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 6, 2011


Sirona Dental Systems, Inc.

By:		/s/ SIMONE BLANK
		Simone Blank, Executive Vice President and Chief Financial Officer
		(Principal Financial and Accounting Officer)
		(Duly authorized signatory)

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company